Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 6/20 | 0.82 |
| ▸ | SRC | P12931 | 5/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.49 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767282 | 0.91 | MAP3K8 (0.75) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL4766908 | 0.91 | MAP3K8 (0.79) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL4769717 | 0.91 | MAP3K8 (0.79) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL5124436 | 0.91 | MAP3K8 (0.73) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL2369875 | 0.90 | MAP3K8 (1.00) | MAP3K8MAPK13EIF2AK2MAPK12MAPK11 | |
| SCHEMBL5118160 | 0.89 | MAP3K8 (0.85) | MAP3K8MAPK13EIF2AK2MAPK12MAPK11 | |
| SCHEMBL5111301 | 0.87 | MAP3K8 (0.69) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL5124935 | 0.86 | MAP3K8 (0.72) | MAP3K8SRCMAPK13EIF2AK2MAPK12 | |
| SCHEMBL4776993 | 0.86 | MAP3K8 (0.67) | MAP3K8SRCMAP2K1STK4EGFR | |
| SCHEMBL5111367 | 0.82 | MAP3K8 (0.67) | MAP3K8SRCMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | MAP3K8 99/4885SRC 2898/4885MAPK13 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.